Eisai commences drug development operations at US facility

The facility aims to provide personalized medicine for different types of cancer, based on the latest genetic research findings and advances in synthetic organic chemistry.

H3 Biomedicine intends to streamline preclinical and clinical research and shorten the overall development time by effectively conducting biomarker research.

The facility’s drug discovery strategy involves identification of drug targets that define the root cause of the cancer by making use of bioinformatics technology and cancer biology.

H3 Biomedicine also utilizes next-generation synthetic organic chemistry to create a compound library that would lead to the development of novel small-molecule drugs.